$INTI
Inhibitor Therapeutics, Inc.

2020 Q4 Form 10-Q Financial Statement

#000119312520294045 Filed on November 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $53.03K $270.3K $262.4K
YoY Change -82.0% -15.12% -20.95%
% of Gross Profit
Research & Development $0.00 $32.47K $52.66K
YoY Change -100.0% -91.09% -82.65%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $55.74K $302.8K $315.0K
YoY Change -91.26% -55.66% -50.43%
Operating Profit -$302.8K -$315.0K
YoY Change -55.66% -50.43%
Interest Expense -$110.00 $10.00 $150.00
YoY Change -105.37% -99.77% -94.66%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$55.85K -$302.8K -$314.9K
YoY Change -91.22% -55.38% -50.23%
Income Tax
% Of Pretax Income
Net Earnings -$55.85K -$302.8K -$314.9K
YoY Change -91.22% -55.38% -50.23%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$149.50 -$811.40 -$850.00
COMMON SHARES
Basic Shares Outstanding 373.6M 373.6M 370.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $75.06K $36.71K $137.3K
YoY Change -90.66% -97.32% -93.22%
Cash & Equivalents $75.06K $36.71K $137.3K
Short-Term Investments
Other Short-Term Assets $32.29K $35.29K $40.03K
YoY Change -23.93% -30.34% 5.31%
Inventory
Prepaid Expenses $32.29K $35.29K $40.03K
Receivables
Other Receivables
Total Short-Term Assets $107.4K $72.00K $177.3K
YoY Change -87.31% -94.94% -91.4%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $24.41K $31.73K $39.05K
YoY Change -54.55% -48.0% -42.86%
Total Long-Term Assets $24.41K $31.73K $39.05K
YoY Change -54.55% -48.0% -42.86%
TOTAL ASSETS
Total Short-Term Assets $107.4K $72.00K $177.3K
Total Long-Term Assets $24.41K $31.73K $39.05K
Total Assets $131.8K $103.7K $216.4K
YoY Change -85.36% -93.01% -89.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $269.4K $251.5K $158.5K
YoY Change -14.73% -12.05% -18.86%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $30.04K $23.11K $16.18K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $425.4K $458.5K $461.6K
YoY Change -1.32% 27.75% 51.45%
LONG-TERM LIABILITIES
Long-Term Debt $66.56K $18.49K $25.42K
YoY Change
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Liabilities $3.067M $3.018M $3.025M
YoY Change 2.22% 0.62% 0.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $425.4K $458.5K $461.6K
Total Long-Term Liabilities $3.067M $3.018M $3.025M
Total Liabilities $3.492M $3.477M $3.487M
YoY Change 1.77% 3.52% 5.51%
SHAREHOLDERS EQUITY
Retained Earnings -$57.17M -$57.07M -$56.71M
YoY Change 2.25% 3.33% 4.06%
Common Stock $49.85M $49.73M $49.48M
YoY Change 0.87% 0.69% 0.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.360M -$3.373M -$3.271M
YoY Change
Total Liabilities & Shareholders Equity $131.8K $103.7K $216.4K
YoY Change -85.36% -93.01% -89.85%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$55.85K -$302.8K -$314.9K
YoY Change -91.22% -55.38% -50.23%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$16.65K -$100.6K -$207.0K
YoY Change -97.07% -81.83% -65.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.00K 0.000 41.60K
YoY Change -100.0% -97.23%
NET CHANGE
Cash From Operating Activities -16.65K -100.6K -207.0K
Cash From Investing Activities
Cash From Financing Activities 55.00K 0.000 41.60K
Net Change In Cash 38.35K -100.6K -165.4K
YoY Change -106.75% -84.59% -118.49%
FREE CASH FLOW
Cash From Operating Activities -$16.65K -$100.6K -$207.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
31731
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
53700
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36707
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803816
CY2020Q3 us-gaap Assets
Assets
103730
CY2019Q4 us-gaap Assets
Assets
899966
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
35292
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
42450
CY2020Q3 us-gaap Assets Current
AssetsCurrent
71999
CY2019Q4 us-gaap Assets Current
AssetsCurrent
846266
CY2020Q3 us-gaap Liabilities
Liabilities
3477007
CY2019Q4 us-gaap Liabilities
Liabilities
3431101
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
251531
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
315940
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
133465
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14339
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
458518
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
431101
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
37364
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
37045
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
103730
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
899966
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49694707
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49384953
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57066214
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55913999
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-3373277
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32468
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
364442
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
182584
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
864812
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
270306
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
318479
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-302774
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-682921
us-gaap Operating Income Loss
OperatingIncomeLoss
-1003260
us-gaap Operating Income Loss
OperatingIncomeLoss
-2110021
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
4373
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1182
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12494
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-302767
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-678548
us-gaap Net Income Loss
NetIncomeLoss
-1002078
us-gaap Net Income Loss
NetIncomeLoss
-2097527
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
373150486
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
371354198
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370427615
CY2020Q3 us-gaap Revenues
Revenues
0
CY2019Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
820676
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1245209
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
302774
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
682921
us-gaap Operating Expenses
OperatingExpenses
1003260
us-gaap Operating Expenses
OperatingExpenses
2110021
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2531135
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
16819
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-384417
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-2948596
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
42753
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-314894
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-3270600
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
49953
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
32351
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
131031
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-786288
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
81614
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-632691
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
27117
CY2020Q3 us-gaap Dividends Payable Current
DividendsPayableCurrent
50411
CY2019Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100822
CY2020Q3 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
23111
CY2020Q3 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
18489
CY2020Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2020Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
50411
CY2019Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
50410
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
150137
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
149588
CY2020Q3 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-353178
CY2019Q3 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-728958
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-1152215
inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-2247115
us-gaap Profit Loss
ProfitLoss
-1002078
us-gaap Profit Loss
ProfitLoss
-2097527
us-gaap Share Based Compensation
ShareBasedCompensation
109525
us-gaap Share Based Compensation
ShareBasedCompensation
239762
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-29127
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12605
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
54717
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-292189
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-808709
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2137349
inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
0
inti Proceeds From Advances Of Royalties Related Party
ProceedsFromAdvancesOfRoyaltiesRelatedParty
2500000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
41600
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41600
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2400822
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-767109
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
263473
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1108713
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1372186
us-gaap Stock Issued1
StockIssued1
200348
us-gaap Stock Issued1
StockIssued1
99946
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
50411
inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
50410
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
inti Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2020Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2020Q3 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
200548
CY2020Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
50411
CY2019Q1 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
99946
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-572275
CY2019Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-1173215
CY2019Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
50410
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-1875056
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
373635873
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
373635873
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
373635873
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370446185
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370446185
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Payments Of Dividends
PaymentsOfDividends
0
us-gaap Payments Of Dividends
PaymentsOfDividends
99178
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies

Files In Submission

Name View Source Status
0001193125-20-294045-index-headers.html Edgar Link pending
0001193125-20-294045-index.html Edgar Link pending
0001193125-20-294045.txt Edgar Link pending
0001193125-20-294045-xbrl.zip Edgar Link pending
d24961d10q.htm Edgar Link pending
d24961dex311.htm Edgar Link pending
d24961dex312.htm Edgar Link pending
d24961dex321.htm Edgar Link pending
d24961dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inti-20200930.xml Edgar Link completed
inti-20200930.xsd Edgar Link pending
inti-20200930_cal.xml Edgar Link unprocessable
inti-20200930_def.xml Edgar Link unprocessable
inti-20200930_lab.xml Edgar Link unprocessable
inti-20200930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending